The biology and therapeutic targeting of the proprotein convertases.
- Published in:
- 2012
- By:
- Publication type:
- journal article
Works matching IS 14741776 AND DT 2012 AND VI 11 AND IP 5
Results: 31
1
2
Glybera and the future of gene therapy in the European Union.
- Published in:
- 2012
- By:
- Publication type:
- Letter
3
In this issue.
- Published in:
- Nature Reviews Drug Discovery, 2012, v. 11, n. 5, p. 333, doi. 10.1038/nrd3724
- Publication type:
- Article
4
Anticancer drugs: Epigenetic reprogramming sensitizes leukaemia to drug treatment.
- Published in:
- 2012
- By:
- Publication type:
- journal article
5
Stephen Frye.
- Published in:
- 2012
- Publication type:
- Interview
6
Experience and further development with the Voluntary Harmonization Procedure for multinational clinical trials in the European Union.
- Published in:
- 2012
- By:
- Publication type:
- Letter
7
Stephen Frye. Interview by Asher Mullard.
- Published in:
- 2012
- By:
- Publication type:
- Journal Article
8
The biology and therapeutic targeting of the proprotein convertases.
- Published in:
- Nature Reviews Drug Discovery, 2012, v. 11, n. 5, p. 367, doi. 10.1038/nrd3699
- By:
- Publication type:
- Article
9
Trial watch: Genetic association studies link interleukin-6 receptor to coronary heart disease.
- Published in:
- Nature Reviews Drug Discovery, 2012, v. 11, n. 5, p. 342, doi. 10.1038/nrd3737
- By:
- Publication type:
- Article
10
News in brief.
- Published in:
- Nature Reviews Drug Discovery, 2012, v. 11, n. 5, p. 341, doi. 10.1038/nrd3734
- Publication type:
- Article
11
Finding the sweet spot: the role of nature and nurture in medicinal chemistry.
- Published in:
- Nature Reviews Drug Discovery, 2012, v. 11, n. 5, p. 355, doi. 10.1038/nrd3701
- By:
- Publication type:
- Article
12
Neurodegenerative disease: Taming the RAGE of Alzheimer's disease.
- Published in:
- 2012
- By:
- Publication type:
- journal article
13
Epigenetic protein families: a new frontier for drug discovery.
- Published in:
- Nature Reviews Drug Discovery, 2012, v. 11, n. 5, p. 384, doi. 10.1038/nrd3674
- By:
- Publication type:
- Article
14
Deal watch: Alcon invests in first non-surgical therapy for common eye disorder.
- Published in:
- Nature Reviews Drug Discovery, 2012, v. 11, n. 5, p. 342, doi. 10.1038/nrd3736
- By:
- Publication type:
- Article
15
Drug development risk and the cost of capital.
- Published in:
- Nature Reviews Drug Discovery, 2012, v. 11, n. 5, p. 347, doi. 10.1038/nrd3722
- By:
- Publication type:
- Article
16
Measuring the value of public-private partnerships in the pharmaceutical sciences.
- Published in:
- Nature Reviews Drug Discovery, 2012, v. 11, n. 5, p. 419, doi. 10.1038/nrd3078-c1
- By:
- Publication type:
- Article
17
Patent watch.
- Published in:
- Nature Reviews Drug Discovery, 2012, v. 11, n. 5, p. 344, doi. 10.1038/nrd3735
- By:
- Publication type:
- Article
18
Experience and further development with the Voluntary Harmonization Procedure for multinational clinical trials in the European Union.
- Published in:
- Nature Reviews Drug Discovery, 2012, v. 11, n. 5, p. 419, doi. 10.1038/nrd3202-c2
- By:
- Publication type:
- Article
19
Anti-NGF painkillers back on track?
- Published in:
- Nature Reviews Drug Discovery, 2012, v. 11, n. 5, p. 337, doi. 10.1038/nrd3732
- By:
- Publication type:
- Article
20
Cancer genomics: Constructing a 'cancerpaedia'.
- Published in:
- 2012
- By:
- Publication type:
- journal article
21
Antibacterial drugs: Overcoming MRSA resistance.
- Published in:
- Nature Reviews Drug Discovery, 2012, v. 11, n. 5, p. 354, doi. 10.1038/nrd3742
- By:
- Publication type:
- Article
22
Neurodegenerative disease: The stress of misfolding.
- Published in:
- 2012
- By:
- Publication type:
- journal article
23
Lead discovery: Small-molecule inhibitors of cytoplasmic dynein.
- Published in:
- Nature Reviews Drug Discovery, 2012, v. 11, n. 5, p. 354, doi. 10.1038/nrd3740
- By:
- Publication type:
- Article
24
Glybera and the future of gene therapy in the European Union.
- Published in:
- Nature Reviews Drug Discovery, 2012, v. 11, n. 5, p. 419, doi. 10.1038/nrd3572-c1
- By:
- Publication type:
- Article
25
Neuromuscular disorders: Turning up the heat (shock).
- Published in:
- 2012
- By:
- Publication type:
- journal article
26
Oncology trials gear up for high-throughput sequencing.
- Published in:
- Nature Reviews Drug Discovery, 2012, v. 11, n. 5, p. 339, doi. 10.1038/nrd3733
- By:
- Publication type:
- Article
27
Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab.
- Published in:
- Nature Reviews Drug Discovery, 2012, v. 11, n. 5, p. 401, doi. 10.1038/nrd3705
- By:
- Publication type:
- Article
28
Innovation and value-driven engineering.
- Published in:
- Nature Reviews Drug Discovery, 2012, v. 11, n. 5, p. 335, doi. 10.1038/nrd3725
- By:
- Publication type:
- Article
29
Cancer: Intratumour heterogeneity.
- Published in:
- Nature Reviews Drug Discovery, 2012, v. 11, n. 5, p. 354, doi. 10.1038/nrd3741
- By:
- Publication type:
- Article
30
Anticancer drugs: Identifying tumour-assocated antigens.
- Published in:
- Nature Reviews Drug Discovery, 2012, v. 11, n. 5, p. 354, doi. 10.1038/nrd3743
- By:
- Publication type:
- Article
31
Ivacaftor.
- Published in:
- Nature Reviews Drug Discovery, 2012, v. 11, n. 5, p. 349, doi. 10.1038/nrd3723
- By:
- Publication type:
- Article